Skip to main content

Table 5 Baseline characteristic and therapy time of relapse and sustained response (SR) patients after discontinuation

From: Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative

Characteristic SR (n=45) Relapse (n=19) P value
HBV DNA - log10 IU/mL 5.5±1.5 5.5±1.5 0.928
ALT – × ULN 3.0 (1.5-6.3) 1.5 (1.2-5.1) 0.154
Age - years 34±11 37±11 0.310
Man - no. (%) 34 (75.6) 14 (73.7) 0.874
Time of achieving undetectable HBV DNA levels – weeks 12 (12–24) 16 (12–24) 0.412
Consolidation therapy - weeks 120 (96–156) 144 (96–144) 0.798
Genotype B - no. (%) 19 (65.5) 10 (34.5) 0.445
Genotype C - no. (%) 26 (74.3) 9 (25.7)